Crinetics Pharmaceuticals Stock Alpha and Beta Analysis
| CRNX Stock | USD 57.03 0.96 1.71% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Crinetics Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Crinetics Pharmaceuticals over a specified time horizon. Remember, high Crinetics Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Crinetics Pharmaceuticals' market risk premium analysis include:
Beta 0.96 | Alpha (0) | Risk 2.44 | Sharpe Ratio 0.0582 | Expected Return 0.14 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Crinetics |
Crinetics Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Crinetics Pharmaceuticals market risk premium is the additional return an investor will receive from holding Crinetics Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Crinetics Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Crinetics Pharmaceuticals' performance over market.| α | -0.002 | β | 0.96 |
Crinetics Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Crinetics Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Crinetics Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Crinetics Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Crinetics Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Crinetics Pharmaceuticals shares will generate the highest return on investment. By understating and applying Crinetics Pharmaceuticals stock market price indicators, traders can identify Crinetics Pharmaceuticals position entry and exit signals to maximize returns.
Crinetics Pharmaceuticals Return and Market Media
The median price of Crinetics Pharmaceuticals for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 53.83 with a coefficient of variation of 5.72. The daily time series for the period is distributed with a sample standard deviation of 3.12, arithmetic mean of 54.57, and mean deviation of 2.68. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Crinetics Pharmaceuticals announces executive departure - Investing.com | 09/17/2024 |
2 | Disposition of 14375 shares by Pizzuti Dana of Crinetics Pharmaceuticals at 54.63 subject to Rule 16b-3 | 10/03/2024 |
3 | Crinetics Pharmaceuticals Inc Q2 2024 Earnings Call Highlights Strategic Advances Amid ... | 10/09/2024 |
4 | Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635 | 10/10/2024 |
5 | Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 | 10/16/2024 |
6 | China Universal Asset Management Co. Ltd. Acquires 6,128 Shares of Crinetics Pharmaceuticals, Inc. | 10/30/2024 |
7 | Esperion Therapeutics Reports Q3 Loss, Lags Revenue Estimates | 11/07/2024 |
8 | Crinetics Pharmaceuticals Announces November 2024 Inducement Grants UnderNasdaq Listing Rule 5635 | 11/11/2024 |
9 | Crinetics unveils new NDC asset shares target raised to 81 by H.C. Wainwright | 11/13/2024 |
10 | Driehaus Capital Management LLC Acquires Shares in Apogee Therapeutics Inc | 11/14/2024 |
11 | Steven Cohens Recent Transaction in Crinetics Pharmaceuticals Inc | 11/15/2024 |
12 | Victory Capital Management Inc. Purchases 116,657 Shares of Crinetics Pharmaceuticals, Inc. - MarketBeat | 11/20/2024 |
About Crinetics Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Crinetics or other stocks. Alpha measures the amount that position in Crinetics Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 21.55 | 12.45 | 13.07 | 17.96 | Net Debt To EBITDA | 1.85 | 0.18 | 0.0143 | 0.0136 |
Crinetics Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Crinetics Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Crinetics Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Crinetics Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Crinetics Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Crinetics Pharmaceuticals' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Crinetics Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.